Etranacogene Dezaparvovec

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Correction to "Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec".

Correction to "Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec".

Journal: CPT: pharmacometrics & systems pharmacology

Published: July 28, 2026

Etranacogene dezaparvovec in hemophilia B: early safety insights.

Etranacogene dezaparvovec in hemophilia B: early safety insights.

Journal: Recenti progressi in medicina

Published: July 16, 2026

Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation.

Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 28, 2026

Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B.

Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Published: April 06, 2026

Gene Therapy in Hemophilia: Clinical Advances, Immunological Challenges, and Emerging Therapeutic Perspectives.

Gene Therapy in Hemophilia: Clinical Advances, Immunological Challenges, and Emerging Therapeutic Perspectives.

Journal: International journal of molecular sciences

Published: April 01, 2026

Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec.

Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec.

Journal: CPT: pharmacometrics & systems pharmacology

Published: March 19, 2026

CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges.

CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges.

Journal: Molecular therapy. Nucleic acids

Published: January 07, 2026

Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trials.

Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trials.

Journal: Trials

Published: December 11, 2025

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.

Journal: The New England journal of medicine

Published: December 08, 2025

Deconstructing gene therapy in hemophilia for the clinician.

Deconstructing gene therapy in hemophilia for the clinician.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial.

Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial.

Journal: Research and practice in thrombosis and haemostasis

Published: November 03, 2025

Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.

Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.

Journal: Journal of blood medicine

Published: October 22, 2025

Showing 1-12 of 67

Last Updated: 09/26/2026